VERDOT appoints Charles Ruban as President and CEO of the Group to accelerate international development and support the group’s next growth phase

VERDOT Ips², supported by its new majority shareholders, Qualium Investissement and Lauxera Capital Partners, announces the appointment of Charles Ruban as President of Verdot Ips², in order to accelerate the Group’s international development and pursue the development of the product range on high value-added technologies for the health industry.

With more than 20 years of international experience in the biopharmaceutical and medical industries, Charles Ruban has built up his expertise as an international healthcare executive by working in various key positions. He has led and contributed to the international development of major healthcare companies, developed strategic alliances, and launched therapeutic biologics in major pharmaceutical markets such as Europe, the US and Japan.

Prior to joining Verdot Ips², Charles Ruban was since 2019 Deputy CEO of HTL Biotechnology, a leader in the development and production of medical biopolymers. Formerly, he was appointed COO of DBV Technologies in 2018, where he supported its development in France and the US.

After starting his professional career in 1995 at Eurogroup Consulting, Charles Ruban spent 9 years (2003-2012) at Stallergenes, where he developed his biopharmaceutical expertise.

Charles Ruban graduated from the Ecole Centrale de Lyon and holds a Master’s degree in Biological and Medical Engineering from the Université Claude Bernard Lyon 1. He also achieved an Executive MBA at INSEAD in 2008.

Charles Ruban, New President of VERDOT Ips² states: “I am very pleased to join VERDOT Ips², which has established itself as one of the undisputed leaders in the design and manufacturing of molecule separation solutions for the biotechnology and biopharmaceutical industries. The recent acquisition of the Group by Qualium Investissement and Lauxera Capital Partners is the proof of our ambition and dynamism to carry out our development projects on all scales.”

Eric Merlot, Outgoing President of VERDOT Ips² explains: “I am very proud to hand over the presidency of the Group to Charles Ruban and I am convinced that his experience and expertise in the healthcare sector and in international development will be huge assets in structuring the company and pursuing our strong growth.”

Pierre Moustial, Founder of Lauxera Capital Partners comments: “Charles Ruban’s professionalism and experience with French healthcare companies combined to his mastery of international issues are real strategic advantages for the future growth of VERDOT Ips², and we are delighted to have him by our side in this new deployment phase of the Group.”

Jacques Pancrazi, Deputy Managing Director of Qualium Investissement highlights: “The appointment of Charles Ruban as the new CEO of VERDOT Ips² will enable the Group to fully implement its new development strategy. We are very proud to be able to support him in achieving the ambitions we all have for Verdot.”

About VERDOT Ips²
Founded in the 1950s, VERDOT became in the 1990s a company specialized in the design and manufacturing of solutions for the separation of molecules by liquid chromatography and tangential filtration, mainly for the biopharmaceutical sector. The equipment and consumables marketed by VERDOT Ips² are critical products in the production of active ingredients used in biomedicines and vaccines, as well as in the production of certain living molecules. Based in Riom (Puy-de-Dôme), the company employs 42 people and had a turnover of €18.5 million in 2021, of which more than 90% was generated internationally.
More information: https://www.verdotips2.com/

About Qualium Investissement
Qualium Investissement, a leading institutional fund, is an historic player in the French private equity market with €1 billion under management. Approved by the Autorité des Marchés Financiers, Qualium is 70% owned by its management and 30% by the Caisse des Dépôts et Consignations. Since its creation in 1998, Qualium has invested in more than 70 French companies in all sectors of activity. Qualium provides companies’ management teams with all the expertise and resources they need to achieve ambitious development objectives, particularly internationally and through external growth.
More information: www.qualium-investissement.com
Contact: Marie Delcourt : marie.delcourt@qualium-invest.com | +33 1 81 80 47 49

About Lauxera Capital Partners
Founded in January 2020, Lauxera Capital Partners is an independent management company based in France (Paris) and the United States (San Francisco). Lauxera Capital Partners is committed to the growth of French and European companies in the HealthTech sector. Its first fund, Lauxera Growth I, a fund reserved for professional investors, has been awarded the “Tibi” label by the French government as part of the charter of commitments of institutional investors for the financing of technology companies. Led by a team of Life Sciences company builders and professional healthcare investors with over 50 years of experience, the company aims to support the international expansion of European HealthTech gems.
More information: https://lauxera.com/